Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities? ; volume:23 ; number:1 ; day:30 ; month:9 ; year:2023 ; pages:1-12 ; date:12.2023
BMC surgery ; 23, Heft 1 (30.9.2023), 1-12, 12.2023
- Creator
-
Carvalho, Luís Filipe Abreu de
Gryspeerdt, Filip
Rashidian, Niki
Hove, Kobe Van
Maertens, Lambertine
Ribeiro, Suzane
Hoorens, Anne
Berrevoet, Frederik
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12893-023-02200-6
- URN
-
urn:nbn:de:101:1-2024020512380645143073
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Carvalho, Luís Filipe Abreu de
- Gryspeerdt, Filip
- Rashidian, Niki
- Hove, Kobe Van
- Maertens, Lambertine
- Ribeiro, Suzane
- Hoorens, Anne
- Berrevoet, Frederik
- SpringerLink (Online service)
Other Objects (12)
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer
Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Conference
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer